RT Journal Article
T1 Oral fosfomycin for the treatment of lower urinary tract infections among kidney transplant recipients—Results of a Spanish multicenter cohort
A1 López Medrano, Francisco
A1 Fernández Ruiz, Mario
A1 Origüen Sabater, Julia
A1 Escudero Portugués, Rosa María
A1 Candel González, Francisco Javier
A1 Pérez Flores, Isabel María
A1 Andrés Belmonte, Amado
A1 Aguado García, José María
AB Oral fosfomycin may constitute an alternative for the treatment of lower urinary tract infections (UTIs) in kidney transplant recipients (KTRs), particularly in view of recent safety concerns with fluroquinolones. Specific data on the efficacy and safety of fosfomycin in KTR are scarce. We performed a retrospective study in 14 Spanish hospitals including KTRs treated with oral fosfomycin (calcium and trometamol salts) for posttransplant cystitis between January 2005 and December 2017. A total of 133 KTRs developed 143 episodes of cystitis. Most episodes (131 [91.6%]) were produced by gram-negative bacilli (GNB), and 78 (54.5%) were categorized as multidrug resistant (including extended-spectrum β-lactamase-producing Enterobacteriaceae [14%] or carbapenem-resistant GNB [3.5%]). A median daily dose of 1.5 g of fosfomycin (interquartile range [IQR]: 1.5-2) was administered for a median of 7 days (IQR: 3-10). Clinical cure (remission of UTI-attributable symptoms at the end of therapy) was achieved in 83.9% (120/143) episodes. Among those episodes with follow-up urine culture, microbiological cure at month 1 was achieved in 70.2% (59/84) episodes. Percutaneous nephrostomy was associated with a lower probability of clinical cure (adjusted odds ratio: 10.50; 95% confidence interval: 0.98-112.29; P = 0.052). In conclusion, fosfomycin is an effective orally available alternative for treating cystitis among KTRs.
PB Elsevier
SN 1600-6135
YR 2020
FD 2020-02-01
LK https://hdl.handle.net/20.500.14352/130774
UL https://hdl.handle.net/20.500.14352/130774
LA eng
NO López-Medrano F, Silva JT, Fernández-Ruiz M, Vidal E, Origüen J, Calvo-Cano A, Luna-Huerta E, Merino E, Hernández D, Jironda-Gallegos C, Escudero R, Gioia F, Moreno A, Roca C, Cordero E, Janeiro D, Sánchez-Sobrino B, Montero MM, Redondo D, Candel FJ, Pérez-Flores I, Armiñanzas C, González-Rico C, Fariñas MC, Rodrigo E, Loeches B, López-Oliva MO, Montejo M, Lauzurica R, Horcajada JP, Pascual J, Andrés A, Aguado JM; REIPI, REDinREN, GESITRA-IC/SEIMC. Oral fosfomycin for the treatment of lower urinary tract infections among kidney transplant recipients: results of a Spanish multicenter cohort. Am J Transplant. 2020;20(2):451-62. doi:10.1111/ajt.15614.
NO Financiado con Fondos FEDER
NO European Commission
NO Ministerio de Ciencia, Innovación y Universidades (España)
NO Instituto de Salud Carlos III (España)
DS Docta Complutense
RD 19 abr 2026